Last reviewed · How we verify
AC591
AC591 is a small molecule inhibitor of the PI3K delta subunit.
AC591 is a small molecule inhibitor of the PI3K delta subunit. Used for Relapsed or refractory follicular lymphoma.
At a glance
| Generic name | AC591 |
|---|---|
| Sponsor | Shandong New Time Pharmaceutical Co., LTD |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the PI3K delta subunit, AC591 is thought to modulate immune cell function and potentially treat various immune-related disorders.
Approved indications
- Relapsed or refractory follicular lymphoma
Common side effects
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AC591 CI brief — competitive landscape report
- AC591 updates RSS · CI watch RSS
- Shandong New Time Pharmaceutical Co., LTD portfolio CI